Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Spondyloarthritis
What would be your treatment approach for a patient with concomitant diagnoses of multiple myeloma and axial spondyloarthritis?
Related Questions
For ICI arthritis, how soon do you start DMARDs?
Where do you anticipate using bimekizumab in your sequence of treatment options for a patient with psoriatic arthritis?
How would you manage active severe psoriasis in a patient planning pregnancy, who also has psoriatic arthritis with well-controlled joint symptoms on certolizumab pegol (anti-TNF therapy)?
How would you approach treatment of active axial spondyloarthritis refractory to NSAID in a patient with concurrent autoinflammatory disease on long-term anti-IL-1 therapy?
Are there certain disease domains in a patient with psoriatic arthritis that will make bimekizumab a particularly good option?
What is your approach to use of IL-17 inhibitors in patients with axial spondyloarthritis and a family history of inflammatory bowel disease?
How do you decide between initiating systemic immunotherapy versus local treatment for uveitis with associated HLA-B27 and spondyloarthropathy?
In a patient with psoriatic arthritis and recurrent pericarditis, would you combine abatacept or other biologics with rilonacept?
How would you manage axial stiffness without pain in an elderly gentleman with a distant history of HLA-B27+ axial and peripheral spondyloarthritis, now with SI joint fusion, no peripheral arthritis, normal inflammatory markers, and no response to TNF inhibition?
How do you incorporate disease activity scores and remission targets for axial spondyloarthritis to determine timing and frequency of treatment adjustments?
